Physician profile

James Davin Dickerson

Psychiatric/Mental Health (Nurse Practitioner) · Council Bluffs, IA

NPI 1801839444

$615.79

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$511.67

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ironshore Pharmaceuticals INC. $169.57 2024
Janssen Pharmaceuticals, INC $132.28 2021-2023 Invega Sustenna
Alkermes, INC. $116.71 2024 Lybalvi
Idorsia Pharmaceuticals US INC $115.47 2023 Quviviq
Almatica Pharma LLC $42.89 2021
Lundbeck LLC $25.64 2021
Abbvie INC. $13.23 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Davin Dickerson

$615.79

in general payments reported 2019-2025

Years
2021-2024
Top company
Ironshore Pharmaceuticals INC.

https://glasscript.com/doctor/1386467/james-davin-dickerson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.